UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2022

Biogen Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-19311 33-0112644 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 225 Binney Street, Cambridge, Massachusetts 02142 (Address of principal executive offices; Zip Code) Registrant's telephone number, including area code: (617) 679-2000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) □ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Symbol(s) Name of each exchange on which registered Title of each class Common Stock, \$0.0005 par value BIIB The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). □ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. $\ \square$

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 25, 2022, Brian S. Posner notified Biogen Inc. (the "Company" or "Biogen") that he will retire from the Biogen Board of Directors (the "Board") effective as of the Company's 2022 annual meeting of stockholders. Pursuant to the retirement provisions set forth in the Company's Corporate Governance Principles, Nancy L. Learning will also retire from the Board effective as of the Company's 2022 annual meeting of stockholders.

Mr. Posner's and Ms. Learning's retirement from the Board are not related to any disagreement with the Board or the Company on any matter relating to its operations, policies, or practices.

On January 31, 2022, the Company issued a press release announcing the retirements of Mr. Posner and Ms. Learning from the Board, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The exhibits listed below are furnished as part of this Current Report on Form 8-K

Exhibit Number Description

99.1 Biogen's press release dated January 31, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Inc.

By: /s/ Samuel Ntonme

Samuel Ntonme Assistant Secretary

Date: January 31, 2022